Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award on April 30, 2024, to a new employee. The award consists of non-qualified stock options to purchase 7,800 shares at $1.49 per share. Vesting occurs over four years, with one-fourth vesting after one year and the rest in monthly installments. The award was granted outside Adicet's equity plans under the Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
-
Rhea-AI Summary
Adicet Bio presented preclinical data on ADI-270, showing robust anti-tumor activity and enhanced functional potency in CD70-positive cancers. They are on track to file an IND application for ADI-270 in 2Q 2024. The data will be featured in an oral presentation at ASGCT's 27th Annual Meeting on May 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (ACET) announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference where the President and CEO will join a panel discussion on 'Off-the-Shelf CART - Let's Talk Lupus and Oncology'. The event is scheduled for April 15, 2024, at 3:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
Rhea-AI Summary
Adicet Bio, Inc. granted an inducement award on March 28, 2024, to a new employee, providing non-qualified stock options to purchase 99,400 shares at $2.35 per share. The vesting schedule spans four years, with gradual vesting over monthly installments. The award was granted outside of the equity incentive plans under the 2022 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) expanded its clinical pipeline into autoimmune diseases with FDA clearance for ADI-001, initiating a Phase 1 trial in lupus nephritis in 2Q 2024. The company plans to file IND for ADI-270 in renal cell carcinoma. Adicet extended its cash runway into 2H 2026, positioning itself well for future milestones and clinical execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.42%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) announced Chen Schor, President and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. The event will focus on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
Rhea-AI Summary
Adicet Bio, Inc. (ACET) granted an inducement award to a new hire on February 29, 2024, consisting of 7,000 non-qualified stock options at an exercise price of $2.35 per share. The options will vest over a four-year period, subject to continued employment. The award was issued under Adicet's Inducement Plan outside of the regular equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) announced that Chen Schor, President and CEO, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will feature a live audio webcast accessible on the company's website. Adicet Bio is a clinical stage biotechnology company focusing on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award to a new employee, consisting of 7,000 non-qualified stock options with an exercise price of $2.99 per share. The options will vest over a four-year period, subject to the employee's continued employment. The award was granted outside of Adicet's stockholder-approved equity incentive plans pursuant to the 2022 Inducement Plan, authorized by the compensation committee of the board of directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) announced the closing of its underwritten public offering, raising approximately $98.0 million. The offering included 32,379,667 shares of common stock and pre-funded warrants to purchase 8,445,333 shares. Jefferies, Guggenheim Securities, and Truist Securities were involved in the offering. The securities were offered pursuant to a shelf registration statement filed with the SEC on May 9, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
FAQ
What is the current stock price of Adicet Bio (ACET)?
The current stock price of Adicet Bio (ACET) is $0.91 as of December 20, 2024.
What is the market cap of Adicet Bio (ACET)?
The market cap of Adicet Bio (ACET) is approximately 72.3M.
What is Adicet Bio, Inc.?
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer.
What are the key products in Adicet Bio's pipeline?
The key products include ADI-001, a CAR T cell therapy targeting CD20 for autoimmune diseases and aggressive B cell non-Hodgkin's lymphoma, and ADI-270, an armored CAR T cell candidate targeting CD70 for renal cell carcinoma.
What recent achievements has Adicet Bio made?
Recent achievements include FDA clearance for ADI-001 in lupus nephritis, successful strategic collaborations, significant financing rounds, and promising preclinical data presentations.
How is Adicet Bio financially positioned?
Adicet Bio has a strong cash position with $247.6 million in cash and equivalents as of March 31, 2024, funding operations into the second half of 2026.
What strategic collaborations has Adicet Bio entered into?
Adicet Bio has a strategic collaboration with Regeneron Pharmaceuticals to develop engineered immune-cell therapeutics using its gamma delta T cell allogeneic platform technology.
What is the focus of Adicet Bio's research and development?
Adicet Bio's R&D focuses on creating 'off-the-shelf' gamma delta T cell therapies engineered with CARs and TCRs for cancer and autoimmune diseases.
What are ADI-001 and ADI-270?
ADI-001 is a gamma delta T cell therapy targeting CD20 for non-Hodgkin's lymphoma and autoimmune diseases, while ADI-270 targets CD70 for renal cell carcinoma and other CD70+ cancers.
What makes Adicet Bio's approach unique?
Adicet Bio utilizes gamma delta T cells with CAR and TCR engineering, providing off-the-shelf, allogeneic therapies that offer durable and effective treatments for patients.
What is the significance of the FDA's fast track designation for ADI-001?
The fast track designation for ADI-001 by the FDA facilitates the development and expedites the review process for this promising therapy targeting lupus nephritis.
Where can I find more information about Adicet Bio?
For more information, visit Adicet Bio's official website at https://www.adicetbio.com.
Adicet Bio, Inc.
Nasdaq:ACET
ACET Rankings
ACET Stock Data
72.29M
69.64M
1.59%
76.44%
4.16%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON